The Hypertension Optimal Treatment trial: Aggressive blood pressure lowering is safe, but benefit is still hard to prove

Cleveland Clinic Journal of Medicine

Volumn 66, Issue 2, 1999, Pages 105-111

  Vidt, Donald G ^a,b,c   Pohl, Marc A ^a,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Sixth Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure   (United States)

^d Hypertension Optimal Treatment Trial ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; PLACEBO; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLEEDING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STROKE; TREATMENT OUTCOME; VERTIGO; BLOOD PRESSURE; CEREBROVASCULAR DISEASE; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG COMBINATION; DRUG EFFECT; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR DISORDERS; DIABETES COMPLICATIONS; DIURETICS; DRUG THERAPY, COMBINATION; FELODIPINE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; QUALITY OF LIFE; RISK FACTORS;

EID: 0033071460     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.66.2.105     Document Type: Article

References (14)

1. Hansson L. Zanchetti A, Carruthers SG, et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
2. MacMahon S, Peto R. Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 35:765-774.
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
4. Farnett L, Mulrow CD. Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991; 265:489-495.
5. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321:129-135.
6. Hansson L, Zanchetti A, for the HOT Study Group. The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability, with special reference to age and gender. Blood Press 1995; 4:313-319.
7. Hansson L, Zanchetti A, for the HOT Study Group. The Hypertension Optimal Treatment (HOT) Study: 24-month data on blood pressure and tolerability. Blood Press 1997; 6:313-317.
8. Wiklund I, Hailing K, Ryden-Bergsten T, Fletcher A, on behalf of the HOT Study Group. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) Study. Blood Press 1997; 6:357-364.
9. Kaplan NM. Commentary. J-curve not burned off by HOT study. Lancet 1998; 351:1748-1749.
10. Furberg CD, Psaty BM. Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives? J Am Geriatr Soc 1995; 43:1309-1310.
11. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-652.
12. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.
13. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26:60-69.
14. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.